COPS5 and cancer: It will be promising to explore small molecules which inhibit interaction between Jab1 and CDK2 but don't affect the deneddylase activity of Jab1, which may induce senescence without affecting global proliferation and the cell cycle, resulting in the development of anti-cancer drugs with minimum side effects.